1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The general aim of this study is to compare telmisartan 80 mg with valsartan 160 mg in
hypertensive patients with type 2 diabetes and overt nephropathy with adjusted blood pressure
beyond the target of 130/80 mmHg after one year of treatment.
The primary objective of this study is to show that telmisartan 80 mg is at least as
effective (i.e., not inferior) and possibly superior to valsartan 160 mg in reducing 24 hour
proteinuria after one year of treatment.